Related Experiment Videos
Evidence for the upregulation of osteogenic protein-1 mRNA expression in musculoskeletal neoplasms
K L Weber1, M E Bolander, M G Rock
1Mayo Clinic, Department of Orthopaedic Surgery, Rochester, Minnesota 55905, USA.
Abstract:
Little is known about bone and cartilage tumors at the molecular level; thus, the identification of genes associated with these tumors may be useful as markers and therapeutic targets. To address this issue and to test the hypothesis that abnormal expression of one or more growth factors in the transforming growth factor-beta superfamily is associated with musculoskeletal neoplasia, degenerate primers based on the conserved sequences in these genes were made for screening tumor samples by reverse transcription-polymerase chain reaction. First, these primers were used to obtain a comparative profile between a low-grade chondrosarcoma and its dedifferentiated high-grade counterpart in the same patient. This experiment identified an amplified DNA product in the high-grade sample that was identical to osteogenic protein-1/bone morphogenetic protein-7. Osteogenic protein-1 mRNA expression was 17-fold greater in this high-grade sample than in the low-grade one. Osteogenic protein-1 was highly expressed (three of three) in human osteosarcoma cell lines but was not expressed (zero of four) in normal osteoblast samples. Screening for gene expression of osteogenic protein-1 in 57 osteosarcomas and chondrosarcomas indicated that 44% (range: 38-52%) of them were positive for osteogenic protein-1 mRNA. Screening of breast and prostate tumors revealed a similar association with osteogenic protein-1 mRNA expression.
Insights
This study identifies osteogenic protein-1 (OP-1) as a potential biomarker for bone and cartilage tumors. Elevated OP-1 mRNA expression was found in high-grade tumors and various cancer cell lines, suggesting its role in musculoskeletal neoplasia.
Area of Science:
- Molecular biology
- Oncology
- Biochemistry
Background:
- Bone and cartilage tumors lack detailed molecular understanding.
- Identifying specific genes can aid in developing diagnostic markers and therapeutic strategies.
Purpose of the Study:
- To investigate the role of growth factors in the transforming growth factor-beta superfamily in musculoskeletal neoplasia.
- To identify potential molecular markers for bone and cartilage tumors.
Main Methods:
- Degenerate primers were designed for conserved sequences within the transforming growth factor-beta superfamily.
- Reverse transcription-polymerase chain reaction (RT-PCR) was used to screen tumor samples.
- Comparative analysis was performed between low-grade and high-grade chondrosarcoma from the same patient.
Main Results:
- Osteogenic protein-1 (OP-1), also known as bone morphogenetic protein-7 (BMP-7), was identified as an amplified DNA product in high-grade chondrosarcoma.
- OP-1 mRNA expression was significantly higher (17-fold) in high-grade versus low-grade chondrosarcoma.
- OP-1 was highly expressed in osteosarcoma cell lines but not in normal osteoblasts. 44% of tested osteosarcomas and chondrosarcomas showed positive OP-1 mRNA expression.
- Similar associations were observed in breast and prostate tumors.
Conclusions:
- Osteogenic protein-1 (OP-1) is differentially expressed in bone and cartilage tumors, with higher levels in high-grade malignancies.
- OP-1 shows potential as a diagnostic marker and therapeutic target for musculoskeletal and other cancers.
- Further research into OP-1's role in tumorigenesis is warranted.